TACTILE SYSTEMS TECHNOLOGY INC Q3 FY2024 earnings call

Key Points - Third Quarter Performance: Total revenue grew 5% YOY to $73.1M, with lymphedema up 4.4% YOY to $65.3M and airway clearance up 10.3% YOY to $7.8M. - Market Dynamics: Revenue results fell short of expectations due to Medicare documentation requirements impacting lymphedema sales rep productivity and uneven DME buying patterns in airway clearance. - Commercial Initiatives: Focus on three key initiatives: technology/workflow investments in sales/order ops, development/launch readiness of next-gen lymphedema platform, and generating clinical evidence. - Medicare Policy Update: CMS retiring LCD and reverting to NCD for PCD coverage, expected to improve Medicare channel sales dynamics. - Airway Clearance Status: Sales up YOY but down sequentially due to seasonal factors and uneven DME buying; still optimistic about undiagnosed/undertreated bronchiectasis patients. - New Product: Nimbl, next-gen basic PCD for upper extremity lymphedema, 68% lighter, 40% smaller, with connectivity to Kylee app; expanding to lower extremities in H1 2025. - Capital Allocation: Initiated share repurchase program of up to $30M of outstanding stock, leveraging free cash flow for growth and shareholder value.

Total revenue in the third quarter grew 5% year-over-year to $73.1 million. Lymphedema products (including Flexitouch and Entre Systems) saw revenue increase $2.8 million or 4% to $65.3 million, accounting for approximately 89.3% of total revenue. Airway clearance products (including AffloVest System) saw revenue increase $0.7 million or 10% to $7.8 million, accounting for approximately 10.7% of total revenue. Gross margin was 75% of revenue, up from 70.9% in the third quarter of 2023. Adjusted EBITDA grew 39.3% year-over-year in the third quarter, reflecting continued operating leverage improvement.

Forward-Looking Statements - Full-year 2024 total revenue expected in the range of $292 million to $295 million, reflecting impacts from Medicare documentation and airway clearance DME patterns. - Adjusted EBITDA for 2024 is expected to be $35 million to $37 million, up from previous guidance, driven by improved profitability from gross margin expansion and operational efficiency. - Q4 is expected to benefit from lymphedema seasonality, progress in technology modernization (e-prescribing national launch, CRM tool deployment), and positive clinical results supporting Flexitouch.

Risks - Policy Ambiguity: MACs could still apply interpretations similar to the previous LCD under the NCD, potentially affecting claims adjudication. - DME Buying Patterns: Uneven purchasing behavior by DME customers continues to impact airway clearance sales sequentially. - Medicare Audit Risk: While no increased post-payment audits have been seen, there remains potential for MACs to interpret ambiguous NCD policy language, leading to challenges in claims processing.

Q: Jimmy from William Blair inquired about the surprise in Medicare documentation impact and visibility on Medicare sales improvement.

A: Sheri Dodd responded that Q3 provided greater insight into documentation requirements, with strategies involving technology, process, and human capital enhancements to mitigate impacts. Noting double-digit growth in VA and commercial channels despite Medicare challenges, and expecting policy change to NCD to improve dynamics moving forward.

Q: Izzy from B. Riley asked about headwinds subsiding in 2025 with e-prescribing rollout.

A: Sheri Dodd stated that the shift to sole NCD policy reduces turbulence, with experience operating under NCD and mitigations like e-prescribing and CRM tools, anticipating normalized operations in the future.

Q: Kyle from B. Riley asked about margin expansion factors and PEC training impact.

A: Elaine Birkemeyer highlighted gross margin improvement from product enhancements and manufacturing efficiency. Sheri Dodd noted PEC training conversion aids margin, with 48% of in-home demos performed by PECs in Q3 and plans to continue expanding while considering provider preferences.